GoodRx reports Q4 revenue $198.6M, net income $6.7M; full-year revenue $792.3M, Adj. EBITDA $260.2M

GoodRx Holdings, Inc.

2024-FY EPS reported $0.04 revenue$792,324,000

Q4 2024 revenue of $198.6M, net income $6.7M (3.4% margin), Adjusted EBITDA $67.1M (33.8% margin).
Full year 2024 revenue $792.3M, net income $16.4M (2.1% margin), Adjusted EBITDA $260.2M (32.8% margin).
Q4 operating cash flow $44.7M, full-year $183.9M; over 7 million prescription consumers at quarter end.
Results described as substantially in-line with previous guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.